Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

BB Biotech

SW: BION

Market CapCHF3,163m

Last Close CHF57.1

BION, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech index (in CHF) but managed on a bottom-up basis, with a focused c 20–35 stock portfolio.

More BB Biotech content >

Investment summary

BB Biotech (BION) provided a solid platform of growth for its investors in FY20, with Swiss franc share price and NAV total returns of 19.3% and 24.3% respectively, outperforming the Nasdaq Biotechnology index in NAV terms amid a weaker environment for the US dollar. While the fund’s investment in mRNA platform company Moderna (share price +509% over 12 months) was the standout story after the rapid development of its successful COVID-19 vaccine, the BION team has been focused on backing companies bringing new technologies to bear in a number of innovative areas. This included investments at IPO in companies such as Generation Bio and Relay Therapeutics. BION has declared a cash distribution of 5% (CHF3.60) for FY20, which equates to a current yield of 4.3%.

Content on BB Biotech
BB Biotech – Looking for innovation beyond the pandemic
Investment companies | research Review | 1 March 2021
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.
BB Biotech – fund manager interview
Investment companies | Edison TV | 15 December 2020
BB Biotech – RNA focus provides a possible COVID-19 solution
Investment companies | research Review | 16 April 2020
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.
View more
Register to receive research on BB Biotech as it is published
Sector
Investment companies
Access more Investment companies content
Share price graph
Price performance
%
1m
3m
12m
Actual 1.4 (12.7) (34.3)
Relative* 8.2 (1.3) (26.9)
52-week high/low CHF91.7/CHF51.0
*% relative to local index
Key management
Erich Hunziker Chairman
Claude Mikkelsen Director of IR
Daniel Koller Head of investment management
Dr Silvia Siegfried-Schanz Director, investor relations